Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Enliven Therapeutics, Inc.NASDAQ: ELVN
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q3 FY2026 selling, general & admin of $8.02M rose 16.7% year over year, behind the +35.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.3% from the prior quarter. Over 3 fiscal years it compounded at +63.3% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +42.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $8.02M-2.3% QoQ
- Last fiscal yearDec 2025
- $33.8M+42.2% YoY
- LTMSep 2026
- $36.41M+35.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +16.7% | -100.0% | -116.7 pp |
| 1 year | +42.2% | -100.0% | -142.2 pp |
| 3-year CAGR | +63.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 33.8M USD
- Year-over-year change
- +42.2%
- 4-year CAGR
- +67.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.8M | +42.2% |
| FY2024 | 2024-12-31 | 23.78M | +25.4% |
| FY2023 | 2023-12-31 | 18.96M | +144.0% |
| FY2022 | 2022-12-31 | 7.77M | +81.2% |
| FY2021 | 2021-12-31 | 4.29M | — |
Selling, General & Admin vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's LTM Sep 2026 selling, general & admin of $36.41M is the 8th highest of the 11 companies compared; the peer median is $105.43M.
- Its year-over-year change of +35.2% is the 3rd highest of 11, against a peer median of +17.1%.
- Over three fiscal years its annual growth of +63.3% compares with a peer median of +17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.4B | +8.2% | +11.2% | 24.0% | |
| LTM Jul 2026 | $533.92M | +3.0% | +4.1% | 21.9% | |
| LTM Jun 2026 | $328.54M | +157.1% | +66.4% | — | |
| LTM Mar 2026 | $176.24M | +26.9% | +75.5% | 81.2% | |
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Mar 2026 | $52.28M | -5.2% | +10.5% | — | |
| LTM Jun 2026 | $51.18M | -29.7% | -6.5% | 494.5% | |
| LTM Sep 2026 | $36.41M | +35.2% | +63.3% | — | |
| LTM Mar 2026 | $33.29M | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $31.48M | +21.6% | +23.3% | — | |
| LTM Mar 2026 | $27.19M | +59.1% | +55.2% | — | |
| Peer median (excluding ELVN) | $105.43M | +17.1% | +17.2% | 81.2% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 263K |
| Gross Profit | 0 | 0 | 0 | 0 | (263K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| Selling, General & Admin | 4.29M | 7.77M | 18.96M | 23.78M | 33.8M |
| Operating Expenses | 24.76M | 38.79M | 83.53M | 104.55M | 119.4M |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| EBITDA | (24.63M) | (37.45M) | (71.29M) | (88.48M) | (103.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (24.76M) | (38.79M) | (83.53M) | (104.55M) | (119.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 22K | 1.13M | 11.95M | 15.76M | 15.96M |
| Income Before Tax | (24.74M) | (37.66M) | (71.58M) | (88.79M) | (103.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 232K | 0 |
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| EPS (Diluted) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| Weighted Avg Shares | 7.81M | 6.25M | 35.55M | 47.07M | 56.66M |
| Weighted Avg Shares (Diluted) | 7.82M | 6.25M | 35.55M | 47.07M | 56.66M |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.